According to Gram Research analysis, a protein called LARS2 that is often reduced in nasopharyngeal cancer helps your immune system recognize cancer cells. A 2026 research study found that patients with higher LARS2 levels responded better to immunotherapy, and restoring LARS2 expression made cancer cells more visible to immune cells. The research also showed that eating more leucine-rich foods may naturally increase LARS2 levels and improve how well immunotherapy works against this type of cancer.
Scientists discovered that a protein called LARS2 plays a crucial role in helping your body’s immune system recognize and fight nasopharyngeal cancer (a type of throat cancer). When LARS2 levels are low, cancer cells can hide from immune cells called T cells. Researchers found that boosting LARS2 expression makes cancer cells more visible to the immune system and improves how well immunotherapy drugs work. Interestingly, eating more leucine-rich foods (found in protein sources like meat, eggs, and beans) may naturally increase LARS2 levels and help immunotherapy treatments become more effective against this type of cancer.
Key Statistics
A 2026 research article in the Journal for Immunotherapy of Cancer found that nasopharyngeal cancer patients with higher LARS2 expression had significantly better responses to immunotherapy and improved overall survival compared to patients with lower LARS2 levels.
According to the 2026 study, restoring LARS2 expression in cancer cells increased the display of MHC-I proteins (immune identity markers) on the cell surface, making cancer cells more recognizable to CD8+ T cells and enhancing immune-mediated tumor destruction.
A 2026 research study demonstrated that combining a high-leucine diet with anti-PD-1 immunotherapy in mouse models was significantly more effective at slowing tumor growth than either treatment alone, suggesting dietary intervention may enhance cancer immunotherapy.
The 2026 research revealed that LARS2 expression was substantially downregulated in nasopharyngeal cancer tissue compared to normal tissue, and this reduction correlated with poor immunotherapy response and worse patient outcomes.
The Quick Take
- What they studied: How a protein called LARS2 helps the immune system recognize and attack nasopharyngeal cancer cells, and whether eating more leucine (an amino acid) could improve cancer treatment
- Who participated: The study used cancer tissue samples from nasopharyngeal cancer patients, laboratory cell cultures, and mice with and without immune systems to test different approaches
- Key finding: Gram Research analysis shows that patients with higher LARS2 levels had better outcomes with immunotherapy, and restoring LARS2 expression made cancer cells more visible to immune cells and improved treatment effectiveness
- What it means for you: If you or a loved one has nasopharyngeal cancer being treated with immunotherapy, this research suggests that eating more leucine-rich foods might help the treatment work better. However, this is early-stage research and should not replace standard medical advice from your oncologist
The Research Details
Researchers used multiple approaches to understand how LARS2 works. First, they examined cancer tissue samples from patients to see if LARS2 levels connected to how well patients responded to immunotherapy. Then they conducted laboratory experiments where they grew cancer cells and immune cells together to watch how LARS2 affected their interactions. They also used two types of mice, some without working immune systems and some with normal immune systems, to test whether restoring LARS2 expression could slow tumor growth. Finally, they tested whether adding leucine to the diet of mice with tumors improved the effectiveness of anti-PD-1 immunotherapy (a type of cancer treatment that removes the brakes on immune cells).
This multi-layered approach is important because it moves from observation (looking at patient tissues) to understanding the mechanism (how LARS2 actually works at the cellular level) to testing potential treatments (leucine supplementation). This progression helps researchers understand not just that something works, but why it works and how it might be applied in real patients.
The study was published in the Journal for Immunotherapy of Cancer, a respected peer-reviewed journal. The researchers used both laboratory and animal models before suggesting human applications, which is the appropriate scientific progression. The study examined multiple aspects of the immune response (T cell activity, antigen presentation, and tumor growth), providing multiple lines of evidence. However, animal studies don’t always translate perfectly to humans, so human clinical trials would be needed to confirm these findings in patients.
What the Results Show
The research revealed that LARS2 expression was significantly lower in nasopharyngeal cancer tissue compared to normal tissue. Importantly, patients with higher LARS2 levels had better responses to immunotherapy and better overall survival. When researchers restored LARS2 expression in cancer cells, several beneficial changes occurred: the cells produced more energy through a process called oxidative phosphorylation, and they displayed more MHC-I proteins on their surface. MHC-I proteins are like name tags that help immune cells recognize cancer cells as threats. With more of these name tags visible, CD8+ T cells (the immune cells that kill cancer) could more easily identify and destroy the cancer cells. In mouse models with functioning immune systems, restoring LARS2 expression significantly slowed tumor growth compared to control mice.
The study also discovered that LARS2 works by improving how mitochondria (the energy factories of cells) function. Specifically, LARS2 helps build the proteins that make up the electron transport chain, which is the machinery that generates cellular energy. The researchers found that leucine, an amino acid, is essential for this process. When they supplemented mice with a high-leucine diet, LARS2 expression increased naturally. Most importantly, combining a high-leucine diet with anti-PD-1 immunotherapy (a standard cancer treatment) was more effective at slowing tumor growth than either treatment alone.
This research builds on previous understanding that some cancers evade the immune system by reducing the visibility of their identity markers (MHC-I proteins). However, this is one of the first studies to identify LARS2 and mitochondrial function as key regulators of this immune evasion mechanism in nasopharyngeal cancer. The finding that dietary leucine can influence immune response is novel and suggests a potential non-pharmaceutical way to enhance immunotherapy effectiveness.
The study has several important limitations. While the research used patient tissue samples, the main experiments were conducted in laboratory cells and mice, not in living patients. Mice don’t always respond to treatments the same way humans do. The study didn’t specify the exact number of patient samples analyzed, making it difficult to assess how representative the findings are. Additionally, the research focused specifically on nasopharyngeal cancer, so results may not apply to other cancer types. Finally, while a high-leucine diet showed promise in mice, the optimal amount of leucine for human patients and potential side effects remain unknown.
The Bottom Line
Based on this research, patients with nasopharyngeal cancer undergoing immunotherapy may discuss with their oncologist whether increasing dietary leucine intake could be beneficial. Leucine-rich foods include chicken, beef, fish, eggs, cheese, nuts, and legumes. However, this should only be done under medical supervision and should not replace standard immunotherapy. The evidence is currently strong enough to warrant clinical trials in humans but not yet strong enough to change standard treatment protocols. Confidence level: Moderate, the research is well-designed but limited to laboratory and animal studies.
This research is most relevant to patients with nasopharyngeal cancer, particularly those being treated with immunotherapy. It may also interest oncologists and immunotherapy specialists treating this cancer type. People with family history of nasopharyngeal cancer might find this information useful for understanding prevention strategies. This research does not currently apply to other cancer types or to cancer prevention in healthy individuals.
In the mouse studies, improvements in tumor control were observed within 2-3 weeks of starting the high-leucine diet combined with immunotherapy. However, human responses typically take longer. If this approach were tested in patients, benefits would likely take several weeks to months to become apparent, similar to standard immunotherapy timelines.
Frequently Asked Questions
Can eating more protein help immunotherapy work better for nasopharyngeal cancer?
According to 2026 research, increasing leucine intake (an amino acid in protein-rich foods) may enhance immunotherapy effectiveness by boosting LARS2 expression. However, this finding is from animal studies and requires human clinical trials before becoming standard medical advice. Always consult your oncologist before making dietary changes during cancer treatment.
What foods are high in leucine for cancer patients?
Leucine-rich foods include chicken, beef, fish, eggs, cheese, nuts, seeds, and legumes like beans and lentils. A 2026 study found that high-leucine diets improved immunotherapy response in mice, but optimal amounts for human patients haven’t been established. Work with a registered dietitian to determine appropriate intake for your specific situation.
Does LARS2 affect all types of cancer or just throat cancer?
The 2026 research specifically studied nasopharyngeal cancer and found LARS2 plays a key role in immune evasion for this cancer type. Whether LARS2 has similar importance in other cancers is unknown. Different cancers use different immune-evasion strategies, so findings may not apply broadly.
Is LARS2 testing available for nasopharyngeal cancer patients?
The 2026 research showed that LARS2 levels predict immunotherapy response, but clinical testing for LARS2 is not yet standard practice. This research may eventually lead to LARS2 testing to help doctors predict which patients will benefit most from immunotherapy, but this would require additional clinical validation first.
Can healthy people use leucine supplements to prevent nasopharyngeal cancer?
The 2026 research focused on treating existing cancer, not prevention in healthy people. There is no evidence that leucine supplementation prevents nasopharyngeal cancer in healthy individuals. Standard prevention approaches include avoiding tobacco and alcohol, and screening if you have risk factors.
Want to Apply This Research?
- Track daily leucine intake in grams and correlate with energy levels and treatment side effects. Users could log protein sources (chicken breast = 3.1g leucine per 100g, eggs = 0.9g per egg, almonds = 1.5g per ounce) and monitor patterns over 4-week periods
- Add one leucine-rich protein source to each meal: breakfast (eggs or Greek yogurt), lunch (chicken or fish), dinner (lean beef or legumes). Start with one meal and gradually add to others to assess tolerance and side effects
- Weekly check-ins on energy levels, appetite, and any changes in treatment side effects. Monthly reviews comparing leucine intake to immunotherapy response markers (if available from medical records). Long-term tracking over 3-6 months to identify patterns between dietary changes and treatment effectiveness
This article summarizes research findings and is for educational purposes only. It does not constitute medical advice. Nasopharyngeal cancer is a serious condition requiring professional medical care. Do not make changes to cancer treatment, diet, or supplementation without consulting your oncologist or healthcare provider. The findings described are from laboratory and animal studies and have not yet been tested in human clinical trials. Individual responses to treatment vary significantly. Always work with your medical team before implementing any dietary or treatment changes.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.
